|
Because you should know "The New Biovail" will beat again.
Product revenues for the second quarter of 2009 were $187.7 million, compared with $175.7 million in the second quarter of 2008, a 7% increase that reflects higher revenues from Wellbutrin XL® and the inclusion of revenues from Xenazine®/Nitoman® and Aplenzin™ Hot "Accumulate" Just like the good old days Sentiment : Strong Buy Rating :
 (5 Ratings) |
 |
|
Page
1
of about
1
First
| < Prev
| Next >
| Last
|
Messages in Topic
| Subject | Author | Rating | Time of Post (ET) | ||
|---|---|---|---|---|---|
|
Why am I posting this ? About earning
|
hotoffthegr... |
|
4-Nov-09 03:13 pm |
|
Page
1
of about
1
First
| < Prev
| Next >
| Last
|
0.07